GlassScriptPhysician profile
Ivan Ljubic
NPI 1639273873
$981.07
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $51.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $188.89 | 2019-2020 | |
| Allergan, INC. | $125.05 | 2019 | |
| Amarin Pharma, INC. | $116.66 | 2019 | |
| Avanir Pharmaceuticals, INC. | $101.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.42 | 2019-2020 | |
| Novo Nordisk INC | $51.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.15 | 2019 | |
| Amgen INC. | $34.96 | 2019 | |
| Glaxosmithkline, LLC. | $31.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.13 | 2019 | |
| Merck Sharp & Dohme LLC | $25.89 | 2019 | |
| Mylan Specialty L.P. | $19.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.29 | 2019 | |
| Astellas Pharma US INC | $18.10 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2019 | |
| Horizon Therapeutics Plc | $12.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Ljubic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.